指南与共识产科母胎医学

国际胎儿生长受限指南诊断、监测与管理共识与争议:更新比较

Consensus and controversies of international guidelines for the diagnosis, surveillance, and management of fetal growth restriction: an updated comparison.
指南 / 共识 · Am J Obstet Gynecol · 2026-04-10

该研究通过电子检索Medline(截至2026年3月)系统比较了2010年以来发布的6部国际及国家胎儿生长受限指南,聚焦定义、诊断监测工具和管理策略的共识与分歧。广泛共识包括多普勒(尤其脐动脉及早发型静脉导管)用于风险分层和分娩时机、产前糖皮质激素、硫酸镁、高危妊娠早期阿司匹林及严重早发型伴结构异常时遗传咨询。争议涉及胎儿生长受限与小於胎龄儿的定义、血管生成生物标志物、低分子肝素预防、生长曲线选择、生物物理评分、计算机化胎心监护及引产方法。

要点

  • 多普勒超声(脐动脉及早发型静脉导管)是风险分层和分娩时机的核心工具。
  • 产前糖皮质激素、硫酸镁、高危妊娠早期阿司匹林及严重早发型伴结构异常时遗传咨询获共识。
  • 定义(FGR vs SGA)、血管生成生物标志物、低分子肝素预防及引产方法仍存争议。

核心结论

  • 当前指南在多普勒监测和标准早产干预上趋同,但在定义和多个管理领域仍存在显著异质性。

研究设计与样本

  • 对2010年以来发表的国际或国家胎儿生长受限指南进行结构化比较,最终纳入6部指南(加拿大、英国、法国、SMFM、ISUOG、FIGO),主要发表于2015至2024年。

主要发现

  • 广泛共识包括多普勒(脐动脉及早发型静脉导管,SMFM除外)用于风险分层和分娩时机。
  • 其他共识点包括产前糖皮质激素、预计早产时硫酸镁、高危妊娠早期阿司匹林、严重或早发型FGR伴结构异常时遗传咨询/检测。
  • 不推荐低风险妊娠常规进行晚孕期超声。
  • 争议包括FGR与SGA定义(SMFM生物测量阈值 vs Delphi标准)、血管生成生物标志物常规使用、低分子肝素预防、生长曲线选择、生物物理评分作用、计算机化胎心监护及引产方法。

临床怎么用

  • 临床应以多普勒监测为核心进行风险分层和分娩时机决策,并遵循共识性早产干预措施。
  • 对严重或早发型FGR伴结构异常者提供遗传咨询和检测。
  • 避免在低风险妊娠中常规进行晚孕期超声。

局限性

  • 指南间定义和管理领域存在显著异质性,反映证据水平和资源环境差异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Fetal growth restriction remains a major contributor to perinatal morbidity and mortality, yet its management varies across clinical settings. The aim of this study was to compare areas of consensus and disagreements across contemporary international and national guidelines on the diagnosis, surveillance, and management of fetal growth restriction. Electronic searches of Medline from database inception up to March 2026 using Medical Subject Headings terms and keywords related to fetal growth restriction and guidelines. Critical, structured comparison of national or international guidelines on fetal growth restriction published since 2010. Final inclusion required unanimous agreement from all authors. Prespecified extraction across domains: definition, prediction/prevention, surveillance tools and frequency, delivery timing and mode, and labor induction methods. Dual data checking with consensus resolution. We focused mainly on areas of cross-guideline agreement and divergence in (1) definitions (fetal growth restriction vs small for gestational age; early vs late), (2) diagnostic/surveillance tools (biometry, Doppler, cardiotocography [conventional or computerized], biophysical profile, biomarkers), and (3) management (aspirin/low-molecular-weight heparin, steroids, magnesium sulfate, induction methods, delivery timing/mode). Six guidelines, 3 national (Canada, United Kingdom, and France), 1 US society guideline (Society for Maternal-Fetal Medicine), and 2 international societies (International Society of Ultrasound in Obstetrics and Gynecology and International Federation of Gynecology and Obstetrics) published predominantly between 2015 and 2024 were included. Broad agreement exists on the central role of Doppler-especially umbilical artery and, in early-onset cases, ductus venosus (except for Society for Maternal-Fetal Medicine)-for risk stratification and delivery timing. Other consensus points include antenatal corticosteroids, magnesium sulfate for anticipated preterm birth, early aspirin in high-risk pregnancies, and access to genetic counseling/testing in severe or early-onset fetal growth restriction with structural anomalies. Universal third-trimester ultrasound is not recommended in low-risk pregnancies. Controversies remain on the definition of fetal growth restriction vs small for gestational age (Society for Maternal-Fetal Medicine biometric threshold vs Delphi criteria), routine use of angiogenic biomarkers, low-molecular-weight heparin for prevention, choice of growth charts, the role of the biophysical profile, computerized cardiotocography, and induction methods (mechanical generally favored but with limited evidence). Current guidelines converge on Doppler-based surveillance and standard preterm interventions, but substantial heterogeneity persists in definitions and several management domains, reflecting variable evidence and resource contexts. Priorities include harmonizing definitions, validating surveillance algorithms (notably computerized cardiotocography and ductus venosus), clarifying growth-chart selection, and rigorously testing the added value of angiogenic biomarkers and induction strategies to improve fetal growth restriction outcomes.

来源:Am J Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Di Mascio D, Chauhan SP, Ghi T, et al. Consensus and controversies of international guidelines for the diagnosis, surveillance, and management of fetal growth restriction: an updated comparison. Am J Obstet Gynecol. 2026. PMID: 41967738. doi:10.1016/j.ajog.2026.04.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。